Treatment of Relapsed or Refractory t(8; 21) AML With Targeted AML1-ETO Neoantigen Cytotoxic T Cells (CTL)
Clinical trial NCT06499025 · ENROLLING_BY_INVITATION
Trial details
- NCT number
- NCT06499025
- Sponsor
- BGI, China
- Status
- ENROLLING_BY_INVITATION
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-01
- Primary completion
- 2026-12-30
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.